Copyright
©The Author(s) 2024.
World J Clin Cases. May 26, 2024; 12(15): 2542-2550
Published online May 26, 2024. doi: 10.12998/wjcc.v12.i15.2542
Published online May 26, 2024. doi: 10.12998/wjcc.v12.i15.2542
Table 1 Clinical characteristics of 10 patients with severe pneumonia after solid organ transplantation
| Recipient | Gender | Age | Type of transplanted organ | Transplant time |
| 1 | Male | 46 | Renal transplantation | 27 d |
| 2 | Male | 63 | Renal transplantation | 5 months |
| 3 | Female | 34 | Renal transplantation | 13 months |
| 4 | Male | 55 | Liver transplantation | 7 d |
| 5 | Male | 56 | Renal transplantation | 4 months |
| 6 | Female | 27 | Renal transplantation | 5 months |
| 7 | Female | 55 | Renal transplantation | 3 months |
| 8 | Male | 60 | Renal transplantation | 16 yr |
| 9 | Male | 27 | Renal transplantation | 4 months |
| 10 | Female | 40 | Renal transplantation | 7 yr |
Table 2 Treatment protocols of 10 patients with severe pneumonia after solid organ transplantation
| Recipient | Treatment protocols |
| 1 | Carrimycin + Vancocin + Levofloxacin |
| 2 | Carrimycin + Amphotericin B |
| 3 | Carrimycin + Caspofungin + Trimethoprim-sulfamethoxazole |
| 4 | Carrimycin + Meropenem + Linezolid + Caspofungin |
| 5 | Carrimycin + Ganciclovir + Moxifloxacin + Trimethoprim-sulfamethoxazole + Peramivir |
| 6 | Carrimycin + Caspofungin + Piperacillin sodium and tazobactam sodium + Imipenem + Trimethoprim-sulfamethoxazole |
| 7 | Carrimycin + Meropenem + Azithromycin + Caspofungin |
| 8 | Carrimycin + Moxifloxacin + Ganciclovir + Peramivir + Imipenem + Piperacillin sodium and tazobactam sodium + Tigecycline + Linezolid + Fluconazole |
| 9 | Carrimycin + Caspofungin + Trimethoprim-sulfamethoxazole + Imipenem + Moxifloxacin |
| 10 | Carrimycin + Imipenem + Ganciclovir + Voriconazole |
Table 3 Pathogens of 10 patients with severe pneumonia after solid organ
| Recipients | Pathogens |
| 1 | Legionnella + Corynebacterium striatum |
| 2 | Mucor |
| 3 | Pneumocystis jirovecii |
| 4 | Baumanii + Staphylococcus epidermidis |
| 5 | Pneumocystis jirovecii + Cytomegalovirus |
| 6 | Pneumocystis jirovecii |
| 7 | Haemophilus parainfluenzae + Mycoplasma |
| 8 | Acinetobacter + Coronavirus |
| 9 | Acinetobacter |
| 10 | Aspergillus |
Table 4 Outcomes of 10 patients with severe pneumonia after solid organ transplantation
| Recipient | Outcome of transplants | Clinical outcomes |
| 1 | Remove | Abandoning treatment |
| 2 | Normal | Cure |
| 3 | Normal | Death |
| 4 | Normal | Cure |
| 5 | Normal | Cure |
| 6 | Normal | Abandoning treatment |
| 7 | Normal | Cure |
| 8 | Normal | Cure |
| 9 | Normal | Cure |
| 10 | Normal | Cure |
Table 5 Antibacterial spectrum of carrimycin found so far
| Pathogens | Antimicrobial spectrum |
| Gram-positive bacterium | Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus digestae, Other Streptococcus, Staphylococcus aureus, Legionella pneumophila |
| Gram-negative bacterium | Haemophilus influenzae, Moraxella catarrh, Neisseria gonorrhoeae |
| Anaerobe | Digestococcus, Bacteroid, Clostridium, Prevotella, Propionibacterium |
| Atypical pathogens | Mycoplasma pneumoniae, Ureaplasma urealyticum, Chlamydia trachomatis, Chlamydia pneumonia |
- Citation: Cui XQ, Zhang LW, Zhao P, Feng JJ. Efficacy and safety of carrimycin in ten patients with severe pneumonia following solid organ transplantation. World J Clin Cases 2024; 12(15): 2542-2550
- URL: https://www.wjgnet.com/2307-8960/full/v12/i15/2542.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i15.2542
